BrainChip Details Olfactory Capabilities of Identifying Bacteria in the Blood in New Research Report
Laguna Hills, Calif. – November 29, 2023 – BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, today announced the availability of a research paper detailing how neuromorphic computing can be utilized as part of an electric nose system to detect and identify different bacteria in the blood.
With findings achieved through studies by BrainChip Research, “Finding Bacteria in the Blood: Scaling a Hardware-Driven Neuromorphic Solution for Real-Worl E-Nose Applications” presents how a hardware-based, low-power neuromorphic solution can be combined with electronic sensors to create compelling real-world healthcare solutions that are cost-effective, portable and accurate. These assisted devices could significantly speed up disease diagnosis in remote locations, or even outside of traditional clinical facilities.
The paper explores a blood dataset collected as part of the Mednose project at Örebro University. The classifier model developed using Akida™ was able to identify ten different bacteria species in blood samples with a classification accuracy of 97.42%, outperforming previous implementations.
“Leveraging neuromorphic hardware to provide portable, power-efficient solutions for use in the identification of sensory data is a game-changer for a plethora of practical applications, such as e-nose systems,” said Anup Vanarse, Research Scientist at BrainChip. “This latest research paper shows how Akida’s olfactory analysis technology allows for efficient and accurate detection of various strains of bacteria in blood to help with important disease diagnosis. Incorporating beneficial AI within sensory devices will provide the means for massive breakthroughs in the healthcare industry.”
- Forums
- ASX - By Stock
- BRN
- BrainChip Details Olfactory Capabilities of Identifying Bacteria in the Blood in New Research Report
BrainChip Details Olfactory Capabilities of Identifying Bacteria in the Blood in New Research Report
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.0¢ |
Change
0.010(3.70%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
27.5¢ | 29.0¢ | 27.5¢ | $1.004M | 3.592M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 117974 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 554999 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 1157178 | 0.275 |
30 | 851741 | 0.270 |
14 | 667302 | 0.265 |
18 | 665815 | 0.260 |
13 | 316021 | 0.255 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 9007 | 3 |
0.285 | 568713 | 16 |
0.290 | 727561 | 17 |
0.295 | 1099923 | 26 |
0.300 | 1422897 | 33 |
Last trade - 10.27am 07/05/2024 (20 minute delay) ? |
|
|||||
Last
28.5¢ |
  |
Change
0.010 ( 3.86 %) |
|||
Open | High | Low | Volume | ||
28.0¢ | 29.0¢ | 27.8¢ | 1938284 | ||
Last updated 10.45am 07/05/2024 ? |
Featured News
BRN (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online